secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2024-07-09T23:59:59+00:00
Accession:  0001628280-24-031426
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics IND for AVTX-009 active; Phase 2 LOTUS trial in hidradenitis suppurativa to commence
--------------------------------------------------------------------------------

- FDA cleared IND for AVTX-009 (anti-IL-1β mAb) allowing Phase 2 LOTUS trial in moderate-to-severe HS.
- LOTUS is a randomized, placebo-controlled trial of ~180 adults with two AVTX-009 dose regimens; primary endpoint HiSCR75 at Week 16.
- First patient enrollment expected in 2024; AVTX-009 acquired in late March 2024 with IND filed ~3 months later.
- Company believes AVTX-009 may be best-in-class due to target, half-life, and potency allowing convenient dosing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024031426/0001628280-24-031426-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024031426/avtx-20240709.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-031426

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer